Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 6/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 6/20 | 0.40 |
| ▸ | PDE2A | O00408 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31731649 | 0.81 | LMNA (0.49) | LMNAMEN1PABPC1KMT2APGR | |
| SCHEMBL23930346 | 0.81 | LMNA (0.49) | LMNAMEN1PABPC1KMT2APGR | |
| SCHEMBL8311223 | 0.79 | ADORA2B (0.49) | LMNAMEN1PABPC1KMT2APDE3B | |
| SCHEMBL19153391 | 0.73 | LMNA (0.47) | LMNAMEN1PABPC1KMT2APGR | |
| SCHEMBL16455981 | 0.71 | JAK2 (0.52) | MEN1KMT2APGRMAPT | |
| SCHEMBL7220155 | 0.70 | DAO (0.66) | LMNAMEN1KMT2APGRMAOB | |
| SCHEMBL30291984 | 0.70 | LMNA (0.56) | LMNAMEN1PABPC1KMT2APGR | |
| SCHEMBL19657542 | 0.69 | HSD17B10 (0.47) | PDE3BPDE3A | |
| SCHEMBL7220153 | 0.69 | LMNA (0.56) | LMNAMEN1PABPC1KMT2APGR | |
| SCHEMBL2272829 | 0.69 | LMNA (0.69) | LMNAMEN1PABPC1KMT2APDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216301-A1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | LMNA 2013/4885MEN1 3226/4885PABPC1 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.